Kinetics of relapse after pegylated interferon and ribavirin therapy for chronic hepatitis C.

about

Factors associated with success of telaprevir- and boceprevir-based triple therapy for hepatitis C virus infection.

P2860

Q33576531-D753A7BA-F65C-4A6C-BD86-4F027F93C13C

P2860

Kinetics of relapse after pegylated interferon and ribavirin therapy for chronic hepatitis C.

Item

http://www.wikidata.org/entity/Q42278792

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Kinetics of relapse after pegy ...... erapy for chronic hepatitis C.

@en

Kinetics of relapse after pegy ...... erapy for chronic hepatitis C.

@nl

type

Item

label

Kinetics of relapse after pegy ...... erapy for chronic hepatitis C.

@en

Kinetics of relapse after pegy ...... erapy for chronic hepatitis C.

@nl

prefLabel

Kinetics of relapse after pegy ...... erapy for chronic hepatitis C.

@en

Kinetics of relapse after pegy ...... erapy for chronic hepatitis C.

@nl

P1476

Kinetics of relapse after pegy ...... erapy for chronic hepatitis C.

@en

P2093

Astrid Vabret

http://www.w3.org/2001/XMLSchema#string

Catherine Guillemard

http://www.w3.org/2001/XMLSchema#string

Eric Nguyen-Khac

http://www.w3.org/2001/XMLSchema#string

Etienne Brochot

http://www.w3.org/2001/XMLSchema#string

G4 group

http://www.w3.org/2001/XMLSchema#string

Ghassan Riachi

http://www.w3.org/2001/XMLSchema#string

Gilles Duverlie

http://www.w3.org/2001/XMLSchema#string

P2860

New tools for quantifying HIV-1 reservoirs: plasma RNA single copy assays and beyond

Unique NS5b hepatitis C virus gene sequence consensus database is essential for standardization of genotype determinations in multicenter epidemiological studies.

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy

Age and total ribavirin dose are independent predictors of relapse after interferon therapy in chronic hepatitis C revealed by data mining analysis.

EASL Clinical Practice Guidelines: management of hepatitis C virus infection.

Rapid emergence of protease inhibitor resistance in hepatitis C virus.

Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.

Strong correlation between liver and serum levels of hepatitis C virus core antigen and RNA in chronically infected patients

The treatment response of chronically hepatitis C virus-infected patients depends on interferon concentration but not on interferon gene expression in peripheral blood mononuclear cells.

P304

1191-1198

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/JMV.23592

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Jean-christophe Plantier

Philippe Mathurin

P577

2013-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23918537

http://www.w3.org/2001/XMLSchema#string

Kinetics of relapse after pegylated interferon and ribavirin therapy for chronic hepatitis C.

about

P2860

P2860

Kinetics of relapse after pegylated interferon and ribavirin therapy for chronic hepatitis C.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698